Annual general meeting

DGAP-News: SGT German Private Equity GmbH & Co. KGaA: SGT German Private Equity redeems 11 million treasury shares

Retrieved on: 
Thursday, August 18, 2022 - 12:07pm
German Startups Group, SGT, Private equity, Private-equity fund, Treasury, Annual general meeting, Security (finance), Financial services

DGAP-News: SGT German Private Equity GmbH & Co. KGaA

Key Points: 
  • DGAP-News: SGT German Private Equity GmbH & Co. KGaA
    SGT German Private Equity GmbH & Co. KGaA: SGT German Private Equity redeems 11 million treasury shares
    The issuer is solely responsible for the content of this announcement.
  • Frankfurt/Main, 18 August 2022 SGT German Private Equity GmbH & Co. KGaA, a listed Private Equity asset manager, has redeemed its 11,052,200 treasury shares by resolution of today's Annual General Meeting.
  • SGT German Private Equity is a Germany-based listed private equity asset manager with registered office in Frankfurt/Main.
  • From its origin as a leading German venture capital provider under the German Startups Group brand SGT German Private Equity also holds a heritage portfolio of minority stakes in some promising German Startups.

China Automotive Systems Announces Annual Meeting on August 26, 2022

Retrieved on: 
Thursday, August 18, 2022 - 11:00am
People, U.S. Securities and Exchange Commission, CAAS, Storey, Forward-looking statement, FCA, Annual general meeting, Private Securities Litigation Reform Act, Security (finance), Republic, Cisco Webex, COVID-19, Company, Fiat Chrysler Automobiles, FAW Group, Risk, Shareholder, China Automotive Systems, Annual report, Ford Motor Company, Henglong (former city), Motor vehicle

WUHAN, China, Aug. 18, 2022 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced the Annual Meeting of Stockholders of China Automotive Systems, Inc. will be held on Friday, August 26, 2022 at 9:00 AM local time at the Second Floor Meeting Room, D8 Henglong Building, Optics Valley Software Park, No. 1 Guanshan First Avenue, Wuhan City, Hubei Province, the People's Republic of China. The Company has also set up a conference room on August 25, 2022 at 9:00 PM at Henglong USA Corporation, 2546 Elliott Drive, Troy, Michigan, U.S., for the Company's shareholders to participate via a WebEx connection.

Key Points: 
  • CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held on Friday, August 26, 2022 at 9:00 AM local time, or 9:00 PM EDT on August 25, 2022
    WUHAN, China, Aug. 18, 2022 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS)("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced the Annual Meeting of Stockholders of China Automotive Systems, Inc. will be held on Friday, August 26, 2022 at 9:00 AM local time at the Second Floor Meeting Room, D8 Henglong Building, Optics Valley Software Park, No.
  • 1 Guanshan First Avenue, Wuhan City, Hubei Province, the People's Republic of China.
  • Shareholders may access the annual meeting by dialing U.S./Canada +1-408-792-6300, pin number 2632 965 7608, and ask for the China Automotive Systems AGM conference call.
  • A live webcast of the conference call will be available at: https://caas-usa.webex.com/caas-usa/j.php?MTID=m93d47af4c7da5c6291044a30...
    Based in Hubei Province, the People's Republic of China, China Automotive Systems, Inc. is a leading supplier of power steering components and systems to the Chinese automotive industry, operating through ten Sino-foreign joint ventures.

NIAAA: Dr. Paule Joseph Selected as the Inaugural American Academy of Nursing Fellow at the National Academy of Medicine

Retrieved on: 
Wednesday, August 17, 2022 - 3:52pm
Pace University, Multimedia, Monell Chemical Senses Center, Disorder, Eating, Indiana University School of Nursing, NIH, Obesity, American Academy, Diagnosis, University, Annual general meeting, Policy, Smell, Leadership, National Institute of Nursing Research, Brain, National Institute, National academy, Research, Environment, Nursing Research, Health, Health equity, National Institute on Alcohol Abuse and Alcoholism, Patient, Academy, Health policy, Taste, Pangborn Sensory Science Symposium, Fellow, Biology, National Academy of Medicine, Culture, Master of Science in Health Informatics, NINR, AAN, Chemesthesis, NAM, NIAAA, Nursing, Metabolism, FAAN, Pharmaceutical industry, Veterinary medicine, Science, Alcoholism

M.S., FNP-BC, FAAN, is the inaugural 2022-2024 American Academy of Nursing (AAN) Fellow at the National Academy of Medicine (NAM).

Key Points: 
  • M.S., FNP-BC, FAAN, is the inaugural 2022-2024 American Academy of Nursing (AAN) Fellow at the National Academy of Medicine (NAM).
  • Dr. Joseph 's selection will be announced in person at the Annual Meeting of the NAM in Washington, D.C. on Monday, October 17.
  • "I congratulate Dr. Joseph on her selection for this first-of-its-kind fellowship," said George F. Koob, Ph.D., Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
  • Dr. Joseph is a researcher at the NIAAA with a joint appointment at the National Institute of Nursing Research (NINR).

Intellinetics Announces Rescheduling of Annual Meeting

Retrieved on: 
Tuesday, August 16, 2022 - 10:00pm
Annual Meetings of the International Monetary Fund and the World Bank Group, Risk, GLOBE, Annual general meeting, SEC, K-12, Annual, Local, OH, Company, Proxy, State, BPO, OTCQB, Institute for State and Local Governance, THE, Intellinetics, Organization, Shareholder

The Company has recently retained a proxy solicitation firm and intends to reschedule its 2022 Annual Meeting of Stockholders, with a new record date and meeting date to be announced.

Key Points: 
  • The Company has recently retained a proxy solicitation firm and intends to reschedule its 2022 Annual Meeting of Stockholders, with a new record date and meeting date to be announced.
  • This material may be deemed to be solicitation material in respect of the Annual Meeting to be rescheduled and held in approximately early November of 2022.
  • In connection with the Annual Meeting, the Company will be filing a revised definitive proxy statement with the SEC.
  • The definitive proxy statement will be made available to stockholders who are entitled to vote at the Annual Meeting.

Saratoga Investment Corp. Announces Distribution of Proxy Materials for its 2022 Annual Meeting of Stockholders

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm
Annual Meetings of the International Monetary Fund and the World Bank Group, U.S. Securities and Exchange Commission, CLO, NYSE, GLOBE, Annual general meeting, SEC, Investment, Eastern Time Zone, LLC, Annual, Investment Company Act of 1940, LLP, Income, Company, Class F, Partnership, SBIC, JV, Solution, Online gambling, Security (finance), Shareholder

NEW YORK, NY, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE: SAR) (“Saratoga Investment,” “Saratoga” or “the Company”) today announced that the Company commenced distribution of the proxy materials to the Company’s stockholders for the 2022 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 29, 2022.

Key Points: 
  • NEW YORK, NY, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE: SAR) (Saratoga Investment, Saratoga or the Company) today announced that the Company commenced distribution of the proxy materials to the Companys stockholders for the 2022 Annual Meeting of Stockholders (the Annual Meeting) to be held on September 29, 2022.
  • Stockholders of the Companys common stock as of the close of business on July 29, 2022, the record date, may vote at the Annual Meeting.
  • Saratoga Investment has elected to be regulated as a business development company under the Investment Company Act of 1940 and is externally-managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies.
  • The Companys diverse funding sources, combined with a permanent capital base, enable Saratoga Investment to provide a broad range of financing solutions.

Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose™ Goals

Retrieved on: 
Tuesday, August 16, 2022 - 1:00pm
Veterinary, Environment, Pets, Professional Services, Health, Consumer, Environmental, Social and Governance (ESG), Agriculture, Natural Resources, People, FDA, Social Security Government Pension Offset, Wind, Multimedia, Disclosure, Adoption, United, Veterinarian, Farmer, Social, NYSE, Interpersonal relationship, Annual general meeting, Dog, Leadership, Guideline, Disease, African, ELAN, Research, Environment, AT, PETS, ESG, Article, Human, Task force, Animal, Sustainability accounting, Biotechnology, Vaccine, Sustainability Accounting Standards Board, Goal, Introduction, Policy, Health, Silent Scope 2, Food and Drug Administration, Articles of incorporation, Ammonia, Antimicrobial stewardship, AT&T, Lithium, Agriculture, Management, Pharmaceutical industry, Livestock, Color, Food, Elanco

Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report Changing The World One Animal at a Time highlighting the companys progress on relevant ESG topics and metrics.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report Changing The World One Animal at a Time highlighting the companys progress on relevant ESG topics and metrics.
  • View the full release here: https://www.businesswire.com/news/home/20220816005184/en/
    Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose Goals (Graphic: Business Wire)
    The 2021 ESG Report expands on the companys inaugural 2020 ESG Summary, providing updates on the companys sustainability programs, policies and initiatives as well as metrics and targets in several key areas, including workforce diversity and environmental impact.
  • The 2021 report outlines the companys approach to sustainability, called Elancos Healthy Purpose, and goals which align with the United Nations 2030 Sustainable Development Goals - and annual progress on the four interconnected Healthy Purpose pillars Healthier Animals, Healthier People, Healthier Planet and Healthier Enterprise, focusing on key areas in which the Elanco business can make a difference.
  • The position will report to Marcela Kirberger, executive vice president, general counsel & corporate secretary, who chairs the cross-functional Elanco Healthy Purpose steering committee comprised of senior representation from across our business.

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

Retrieved on: 
Tuesday, August 16, 2022 - 11:45am
Biotechnology, Pharmaceutical, Health, MSD, LNP, U.S. Securities and Exchange Commission, Multimedia, Cell, NYSE, Technology, Annual general meeting, YouTube, SEC, Infection, Patent, Tissue, Society, Security (finance), Research, MPM, Patient, MRK, Gene, Instagram, Therapy, COVID-19, Twitter, Merck & Co., Vaccine, RNA, MIT, Coronavirus, News, Science, Lists of diseases, Private Securities Litigation Reform Act, LinkedIn, Animal, RNA transfection, Pharmaceutical industry, Facebook, Merck, Orna

Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease.

Key Points: 
  • Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease.
  • Ornas proprietary oRNA technology creates circular RNAs (oRNAs) from linear RNAs by self-circularization.
  • Our oRNA technology plus novel delivery solutions are designed to unlock the full potential of RNA in therapeutics and vaccines, said Tom Barnes, Chief Executive Officer of Orna.
  • The combined expertise of Orna and Merck aims to accelerate the development of RNA therapeutics for patients in need of better treatment options.

Vertical Capital Income Fund (VCIF) Announces 2022 Annual Meeting and Record Date

Retrieved on: 
Monday, August 15, 2022 - 11:27pm
Multimedia, Risk, NYSE, UPB, Annual general meeting, SEC, Investment, Behringer, Eastern Time Zone, LLC, Income, Program, Closed-end fund, Trustee, Security (finance), Fund, Shareholder

DALLAS, Aug. 15, 2022 /PRNewswire/ -- Vertical Capital Income Fund (NYSE: VCIF) today announced that the Fund's Annual Meeting of Shareholders will be held on September 28, 2022, at 10:00 a.m., Eastern Time, at 41 South High Street, 17th Floor, Columbus, Ohio 43215.

Key Points: 
  • DALLAS, Aug. 15, 2022 /PRNewswire/ -- Vertical Capital Income Fund (NYSE: VCIF) today announced that the Fund's Annual Meeting of Shareholders will be held on September 28, 2022, at 10:00 a.m., Eastern Time, at 41 South High Street, 17th Floor, Columbus, Ohio 43215.
  • The notice of the Annual Meeting of Shareholders will be mailed to shareholders on or about September 12, 2022.
  • At the Annual Meeting of Shareholders, shareholders of the Fund will be asked to re-elect one of the Trustees of the Fund and transact such other business as may properly come before the meeting.
  • Vertical Capital Income Fund (VCIF) is an NYSE-listed closed-end fund that seeks monthly income by investing primarily in performing non-agency residential whole loans secured by real estate.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 15, 2022 - 9:05pm
Lung cancer, U.S. Securities and Exchange Commission, DLBCL, Association, SYK, Risk, American Association, RECIST, University of California, Davis, MS, GLOBE, ORR, UC Davis Comprehensive Cancer Center, Population, Failure, Annual general meeting, Private Securities Litigation Reform Act, Cancer, B-cell lymphoma, Security (finance), UC, Income, NSCLC, DLBC, Neoplasm, Patient, Large-cell lung carcinoma, SAN, NFE2L2, WCLC, Program, Safety, Adenocarcinoma, Doctor of Philosophy, KRAS, AACR, Research, International Association, Webcast, KEAP1, CALA, Nasdaq, American Association for Cancer Research, Investor, Conference, Journal of Thoracic Oncology, ABC, VPS4A, Pharmaceutical industry, Cryptocurrency, VPS4B, NRF2, MD

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
  • Calithera plans to share data from this trial by the first quarter of 2023.
  • Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
  • General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

Retrieved on: 
Monday, August 15, 2022 - 9:05pm
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NUALS Arts and Literary Annual Meet, U.S. Securities and Exchange Commission, Risk, Erasmus MC, Name, NYSE, Inspectorate, Delaware Court of Chancery, Annual general meeting, SEC, Board, Lists of diseases, Hearing, Research, Optimism, Security (finance), Cancer, EAP, Beneficial ownership, Court, Patient, COVID-19, Company, Twitter, Pancreatic cancer, American, Therapy, Form 10-K, CFS, Special access program, Degenerative disease, Rintatolimod, Delaware Court, WHEN, LinkedIn, Chronic fatigue syndrome, AIM, THE, Immune system, Pharmaceutical industry, Ownership, Facebook, Shareholder

The Court of Chancery reconvened the hearing today and denied Mr. Jorgls motion for a TRO.

Key Points: 
  • The Court of Chancery reconvened the hearing today and denied Mr. Jorgls motion for a TRO.
  • The Court scheduled a hearing on Mr. Jorgls motion for a preliminary injunction to be held on October 5, 2022.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Companys lead product, Ampligen (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.